TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03016702

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive stress tests during gait task
Description: Subjects will undergo progressively more complex cognitive stress tests that assess memory and executive function both in sitting and while ambulating on a force sensor mat.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive stress tests during gait task
Description: Subjects will undergo progressively more complex cognitive stress tests that assess memory and executive function both in sitting and while ambulating on a force sensor mat.
Study: NCT01962753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18FAV45
Description: Admnistration of 18FAV45 if patient is compliant with one of those treatment: Seroplex, Zoloft, Deroxat, Venlafaxine, Mirtazapine, Moclamine,
Study: NCT02203279

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rebase II Fast
Description: It is going to be used a direct relining material

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flexacryl
Description: This is going to be used as a second direct relining material

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vertex
Description: This is going to be used as an indirect relining material
Study: NCT04283279

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality exercise
Description: Participants will do exercises in a virtual environment, solving tasks that require cognitive efforts and motor/balance efforts. The virtual environment/tasks will be delivered through a head-mounted display (goggles). Difficulty will progress from standing/sitting, to walking on a treadmill. The environments that will be used will be both over-the-counter environments, as well as in-house designed environments.
Study: NCT04082741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986318
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986318
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Matching BMS-986318

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Matching BMS-986318
Study: NCT02834403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Mitotic inhibitor, cytotoxic
Study: NCT04283279

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation exercise
Description: Vestibular rehabilitation exercises focus on head and eyes movements, as well as whole-body movements. The aim is to facilitate the use of other sensory organs than the vestibular organs, which will also be relevant to persons who are not receiving sufficient sensory information from the auditory system. The exercises will progress as tolerated, under careful supervision of trained therapists.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Participants will not be randomised to either of the exercise interventions, but will be adviced to stay active
Study: NCT02834403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Mitotic inhibitor, cytotoxic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Mitotic inhibitor, cytotoxic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Mitotic inhibitor, cytotoxic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Mitotic inhibitor, cytotoxic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Mitotic inhibitor, cytotoxic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Long-acting calcium channel blocker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Long-acting calcium channel blocker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Long-acting calcium channel blocker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Long-acting calcium channel blocker
Study: NCT01981044

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silk surgical mesh
Description: A CE Marked, 510(k) cleared, knitted, multi-filament, bioengineered, silk mesh indicated for use as a transitory scaffold for soft tissue support and repair
Study: NCT01878474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-8995
Description: TA-8905 5, 10, 25, 50 (fasted and fed), 100 and 150 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-8995
Description: Drug: TA-8995 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-8995
Description: Drug: TA-8995 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-8995
Description: Drug: TA-8995 25, 50, 100 and 150 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single ascending dose in Caucasian men

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Age-effect in Caucasian men

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Gender-effect in Caucasian women

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single ascending dose in Japanese men
Study: NCT01197300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: intravenous infusion
Study: NCT01055119

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Omega-3 fatty acids
Description: duration: 4 month

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fatty acids
Description: duration: 4 month
Study: NCT03635879

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MCTprocal medical food
Description: 32 g MCTprocal (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Milk/tricaprilin oil blend
Description: 154 mL of lactose-free skim milk/21 mL of tricaprilin oil blended and then mixed in 180 mL of water at Hour 0 Day 1

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AC-1207
Description: AC-1207 (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AC-1205
Description: AC-1205 (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1
Study: NCT02834403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Long-acting calcium channel blocker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Long-acting calcium channel blocker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Long-acting calcium channel blocker
Study: NCT02755688

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracoscopic Surgical ablation
Description: Thoracoscopic approach to isolate pulmonary veins, ganglionic plexi ablation and left atrial appendage exclusion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter ablation
Description: Ablation using contact force technology to isolate pulmonary veins and create linear lesions.
Study: NCT02834403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Colony-stimulating factor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Colony-stimulating factor
Study: NCT01479985

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CDM Tool
Description: Participants will be required to complete the CDM tool and receive a tailored print out of their contraceptive options based on survey answers
Study: NCT00708201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alvimopan

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03635879

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AC-1206
Description: AC-1206 (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-1202
Description: AC-1202 (20 g MCT) mixed in 240 mL of water at Hour 0 Day 1
Study: NCT02884479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT-112
Description: Increasing doses of intravenously administered PT-112 in combination with 60 mg/m2 docetaxel every 3 weeks (Q3W) in subjects with advanced solid tumor of any histological type.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Increasing doses of intravenously administered PT-112 in combination with 60 mg/m2 docetaxel every 3 weeks (Q3W) in subjects with advanced solid tumor of any histological type.
Study: NCT03949907

Intervention type: OTHER
Group type: OTHER
Intervention: Nutritional counseling alone
Description: Nutritional counseling consists of a personalized dietary prescription (including sample meal plans and recipe suggestions) tailored on personal eating patterns and food preferences, in order to achieve estimated protein-calorie requirements and to take into account chewing and swallowing abilities. Regular consultation by a registered dietitian will be also provided every 10 days by means of face-to-face interviews (at scheduled follow-up visits - chemotherapy cycle) and telephone interviews (planned between chemotherapy cycles and as required by the patient). In the presence of significant reduction of normal food intake, the use of oral nutritional supplements will be also considered.~In the presence of body weight loss \>10% of the weight recorded at enrollment, patients allocated to this group group will be censored and treated according to current supportive care guidelines, including home parenteral nutrition.
Study: NCT02834403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Colony-stimulating factor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Colony-stimulating factor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Colony-stimulating factor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Colony-stimulating factor
Study: NCT03949907

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early supplemental parenteral nutrition plus nutritional counseling
Description: Patients will receive nutritional counseling in combination with systematic early supplemental home parenteral nutrition since diagnosis.~Supplemental home parenteral nutrition will be prescribed, provided daily and adjusted throughout the study (approximately every 10 days, until the end of the scheduled first-line chemotherapy) according to estimated protein-calorie oral intakes, in order to satisfy estimated requirements. Home parenteral nutrition will be infused mainly during night hours, using multi-chamber bags containing olive oil-based lipid emulsions, when not contraindicated.
Study: NCT01872208

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HAV implantation
Description: Patients will be implanted with a Human Acellular Vessel (HAV) as an above-knee femoro-popliteal bypass graft using standard vascular surgical techniques.
Study: NCT00461331

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Aspart
Description: Either one of these insulins were given to the patient as the second insulin (depending on which was given as the first one, the other insulin was insulin 2). Patients used this insulin in the same dose as they did prior to entering the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Patients were given either insulin Aspart or Lispro in test period 1. Then they were switched to the other insulin in test period 2.
Study: NCT01108978

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dehypotin® 40 mg/day or placebo, once a day, shortly after baseline for 12 consecutive weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dehypotin
Description: Dehypotin® 40 mg/day or placebo, once a day, shortly after baseline for 12 consecutive weeks
Study: NCT02457598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirabrutinib
Description: Capsules or tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirabrutinib
Description: Capsules or tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirabrutinib
Description: Capsules or tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirabrutinib
Description: Capsules or tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirabrutinib
Description: Capsules or tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Tablets administered orally twice daily
Study: NCT02834403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Colony-stimulating factor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin
Description: non-steroidal anti-inflammatory drug
Study: NCT02457598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Tablets administered orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entospletinib
Description: Tablets administered orally
Study: NCT02834403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin
Description: non-steroidal anti-inflammatory drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin
Description: non-steroidal anti-inflammatory drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin
Description: non-steroidal anti-inflammatory drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin
Description: non-steroidal anti-inflammatory drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin
Description: non-steroidal anti-inflammatory drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin
Description: non-steroidal anti-inflammatory drug
Study: NCT00657761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfuvirtide
Description: 90 mg/12h sc for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% saline solution/12h sc for 7 days
Study: NCT02588274

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture is one of the oldest standardized neuromodulatory therapies. The method of acupuncture treatment involves the insertion of needles in acupuncture points according to a system of channels and meridians. The needles are stimulated by manual manipulation, electrical stimulation or heat. The general theory of acupuncture is based on the premise that there are patterns of energy flow through the body that are essential for health. Disruptions of this flow are believed to be responsible for disease. Acupuncture may correct imbalances of flow at identifiable points close to the skin.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo needle
Description: Placebo needle is a type of control without skin penetration based on the application of placebo needles with blunt needle tips.
Study: NCT00079612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: 800mg daily (2x 400mg tabs)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2x 400mg tabs daily
Study: NCT04567316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-radiolabelled BI 1358894
Description: Part 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1358894
Description: Part 2
Study: NCT04438044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-022
Description: ICP-022 The drug product is a white, round, uncoated tablet
Study: NCT02155257

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modafinil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04182555

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bilirubin estimates from Smartphone Application
Description: Bilirubin estimates through color analysis of digital images obtained through smartphone application.
Study: NCT02480712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg fixed-dose combination (FDC) tablet administered orally once daily
Study: NCT02582762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nail gel
Description: apply nail gel on affected nails twice daily for 2 months
Study: NCT03771547

Intervention type: DIAGNOSTIC_TEST
Intervention: ERCP

Intervention type: DIAGNOSTIC_TEST
Intervention: ERCP
Study: NCT02933970

Intervention type: OTHER
Group type: OTHER
Intervention: Telemedicine
Description: Patients will be linked with the provider via two-way video-teleconferencing facilitated by an onsite OAT program staff member
Study: NCT04182555

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Bilirubin concentration measured in standard blood samples
Description: Bilirubin measured in total serum bilirubin.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bilirubin estimates from standard transcutaneous device
Description: Bilirubin estimates performed by transcutaneous device ( Dräger JM-105)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual assessment of jaundice
Description: Degree of jaundice will be assessed by Kramer scale
Study: NCT04097444

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study: NCT03515603

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic resection
Description: Transsphenoidal endoscopic resection of pituitary adenoma

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microsurgical resection
Description: Transsphenoidal microsurgical resection of pituitary adenoma
Study: NCT02284334

Intervention type: OTHER
Intervention: test meal
Description: low- or high-glycemic index test meal, administered during mixed meal tolerance test

Intervention type: OTHER
Intervention: test meal
Description: low- or high-glycemic index test meal, administered during mixed meal tolerance test
Study: NCT01605396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ridaforolimus
Description: Ridaforolimus 10 mg tablet, administered PO at a dose of 10 mg (triplet) or 30 mg (doublet) depending upon randomization, on Days 1-5, 8-12, 15-19, \& 22-26 of 28-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ridaforolimus
Description: Ridaforolimus 10 mg tablet, administered PO at a dose of 10 mg (triplet) or 30 mg (doublet) depending upon randomization, on Days 1-5, 8-12, 15-19, \& 22-26 of 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalotuzumab
Description: Dalotuzumab administered 10 mg/kg IV weekly on Days 1, 8, 15, and 22 of 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Exemestane 25 mg tablet administered PO QD.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: Exemestane 25 mg tablet administered PO QD.
Study: NCT02758886

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Animal assisted activity
Description: Allowed to interact (e.g. talking, petting, scratching, feeding treats, playing with) live animals

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Animal photos
Description: A 10 minute, silent, PowerPoint slide show of a variety of dogs and cats

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Observing human-animal interaction
Description: Participants watched others participate in petting dogs and cats, while they waited in line for 10 minutes. Participants did not physically touch any animals during this time.
Study: NCT03204838

Intervention type: GENETIC
Intervention: IDH mutation test performed at diagnosis
Description: Observation of the test result
Study: NCT02429596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Switch from brand to generic
Study: NCT04747574

Intervention type: DRUG
Group type: OTHER
Intervention: EXO-CD24
Description: The study active treatment is EXO-CD24 -exosomes (natural nano-sized vesicles secreted by human cells) that were engineered to overexpress CD24, aerosolized in normal saline for inhalation via a standard hospital-grade inhalation device, QD for 5 days.
Study: NCT02826044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP2086
Description: The study has 3 doses groups and the 30 subjects were administrated SP2086 50mg,100mg,200mg respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP2086
Description: The study has 3 doses groups and the 30 subjects were administrated SP2086 50mg,100mg,200mg respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP2086
Description: The study has 3 doses groups and the 30 subjects were administrated SP2086 50mg,100mg,200mg respectively.
Study: NCT01564290

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic yogurt
Description: Lactobacilus Rhamnonsus 100000000 UFC per mL. Dosage 50 mL twice daily fo 5 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo probiotic
Description: Lyophilized probiotic, containing 250 mg per sachet dosage to about 2 times a day for 5 days.
Study: NCT01592851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stannous Fluoride
Description: dentifrice containing stannous fluoride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Monofluorophosphate
Description: dentifrice containing Sodium Monofluorophosphate